cas 51019-43-3|| where to buy (R)-2-Acetoxy-2-phenylacetic acid

Produktname:(R)-2-Acetoxy-2-phenylacetic acid

IUPAC Name:(2R)-2-(acetyloxy)-2-phenylacetic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM253292-500g	in stock	ȃƥŗ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 51019-43-3 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:51019-43-3; Molekulare Formel:C10H10O4; Schmelzpunkt:-; SMILES-Code:O=C(O)[C@H](OC(C)=O)C1=CC=CC=C1; Dichte:

: Katalognummer:CM253292; Molekulargewicht:194.19; Siedepunkt:317.8°C at 760 mmHg; Mdl-Nr.:MFCD00004249; Lagerung:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Samuraciclib; Carrick Therapeutics’ Phase 2 Clinical Trial of Samuraciclib combined with Fulvestrant has dosed its first patient. The study targets patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Samuraciclib is a selective oral, first-in-class inhibitor of CDK7. It is involved in the regulation of cancer-causing genes, promotion of uncontrolled cell cycle progression, and increase in resistance to anti-hormone therapy. The comb previously receives the Fast Track Designation from the U.S. FDA.